SLC5A2 and type 2 diabetes mellitus: Xiao-Chun Zeng et al. conducted a study in 2024 to investigate how SGLT2 inhibitors (SGLT2i) reduce albuminuria in patients with type 2 diabetes mellitus (T2DM).